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Inhibition of the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) 
pathway has been the focus of drug development for many 
years. The pathway is dysregulated in a significant percent-
age of solid tumors, including approximately 20% to 35% of 
non–small-cell lung cancers (NSCLC).1 Nevertheless, suc-
cessful targeting of this pathway has been difficult to achieve.2 
Inhibitors of RAS, the most commonly mutated gene in this 
pathway, have not generated successful results in clinical tri-
als. Therefore, inhibition at other points along the pathway has 
been evaluated.
MEK1 and MEK2 are threonine/tyrosine protein 
kinases that are phosphorylated by activated RAF and in 
turn, phosphorylate ERK1 and ERK2, leading to proliferation 
and migration. Mutations in RAS or RAF lead to a sustained 
oncogenic signal and predict response to MEK inhibition in 
laboratory models.3,4 Three MEK inhibitors and an Akt inhibi-
tor were presented in this session at the 12th Annual Targeted 
Therapies of the Treatment of Lung Cancer and will be 
reviewed here.
SUMMARY OF PRESENTATIONS
Selumetinib (AZD6244 or ARRY-142886) is an oral, 
uncompetitive, potent inhibitor of MEK 1/2 (IC
50
 14 nM for 
MEK1). Selumetinib has high specificity for MEK1/2, with 
little activity against a panel of more than 40 other kinases. 
Although a gene-expression profile associated with response 
to selumetinib among cell lines has been demonstrated,5 the 
strongest association was arguably the association with RAS 
mutations.4 When evaluating a large panel of human NSCLC 
cell lines, a significant association was found between sensi-
tivity to the compound and RAS mutational status. Preclinical 
combinations have been an active area of investigation and 
studies have been reported with concomitant VEGF or mTOR 
inhibition.
Clinical development of selumetinib began with a phase 
I trial demonstrating tolerability and preliminary efficacy of 
selumetinib at 100 mg twice daily.6 An acneiform rash was 
the most frequently reported and dose-limiting toxicity. In a 
randomized, open-label, phase II trial of selumetinib versus 
pemetrexed in pretreated NSCLC, selumetinib showed no 
advantage in an unselected population.7 On the basis of the 
preclinical data discussed above, further study specifically in 
RAS or RAF mutated tumors was suggested.
A randomized trial of selumetinib with docetaxel ver-
sus docetaxel alone in patients with RAS-mutated NSCLC has 
completed accrual. At the time of this meeting, data regarding 
this trial had not been formally presented, and the only data 
with respect to the outcome of the trial came from a press 
release. The press release described that the study was pow-
ered for a benefit in overall survival, and although survival 
was numerically superior, the result did not reach statistical 
significance. However, a statistically significant improvement 
in response rate and progression-free survival with the com-
bination of docetaxel and selumetinib was seen in this small 
phase II trial, generating some enthusiasm.
Several selumetinib trials are currently enrolling 
patients, including a phase II study (NCT01229150) in previ-
ously treated NSCLC stratified by KRAS status; mutated KRAS 
patients are randomized to receive selumetinib and erlotinib or 
selumetinib alone, and wild-type KRAS patients are random-
ized to receive selumetinib and erlotinib or erlotinib alone. 
In addition, the drug is being evaluated with thoracic radia-
tion in one trial (NCT01146756) and in two multiarm trials 
(NCT01306045 and NCT01248247) that assign treatment by 
molecular tumor characteristics. Other combinations in vari-
ous tumor types are also under study.
Trametinib (GSK 1120212 or JTP-74057) is a revers-
ible, allosteric MEK1/MEK2 inhibitor with an IC
50
 of 0.7 nM 
for MEK1, and a high specificity as demonstrated by limited 
activity against a panel of 180 other kinases.8 In vitro and in 
vivo models reveal significant activity against tumors harbor-
ing mutant RAF or RAS. A phase I trial using trametinib dem-
onstrated acneiform rash, diarrhea, and rare left ventricular 
cardiac dysfunction as the primary toxicities.9 A reversible 
serous retinopathy was observed at higher doses and seemed 
to be a potential class effect of MEK inhibitors. The recom-
mended phase II dose was 2 mg daily. The half-life was 4.5 
days and sustained target inhibition was seen in pharmacody-
namic studies. Preliminary evidence of activity was demon-
strated in melanoma and pancreatic cancer.
Combination treatment with trametinib is under study 
with agents including gemcitabine, everolimus, pazopanib, 
the BRAF inhibitor GSK 2118436, the Akt inhibitor GSK 
2141795, and the PI3K inhibitors GSK 2126458 and BKM120. 
A multiarm phase I/Ib trial (NCT01192165) is assessing many 
treatment combinations—docetaxel, erlotinib, pemetrexed, 
carboplatin, cisplatin, and nab-paclitaxel—specifically with a 
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goal of identifying appropriate regimens for lung and pancre-
atic cancer treatment. An open-label, randomized phase II trial 
(NCT01362296) in second-line NSCLC that harbors a muta-
tion in KRAS, NRAS, BRAF, or MEK1 is currently recruiting 
patients.
PD-0325901 is a derivative of the first-generation MEK 
inhibitor CI-1040. A maximum tolerated dose of 15 mg twice 
daily was identified in a phase I trial, but late adverse events 
included retinal vein occlusion and neurotoxicity.10 The same 
schedule in a single-arm phase II trial in previously treated 
NSCLC demonstrated significant toxicities whereas an inter-
mittent dosing schedule revealed insufficient anticancer 
activity to warrant future single-agent study in an unselected 
population.11
MK-2206 is an oral pan-Akt inhibitor. The PI3K/Akt 
pathway is frequently activated in cancer. In NSCLC and 
small-cell lung cancer, activity of this pathway has been seen 
with PIK3CA mutations and amplification, AKT mutations, 
and loss of the PTEN tumor-suppressor as well as in tumors 
that do not demonstrate these genetic alterations. MK-2206 
binds Akt in its inactive configuration. Preclinical activity 
has been seen in a panel of NSCLC lines, with the greatest 
activity in a PIK3CA-mutated model.12 Synergy is seen with 
docetaxel, carboplatin, gemcitabine, and erlotinib. Of note, 
combination therapy with selumetinib demonstrated synergy 
and is being evaluated clinically (NCT01021748).13 A phase 
I trial of MK-2206 revealed good tolerance with common 
adverse events of rash, nausea, fatigue, and hyperglycemia. 
The maximum tolerated dose is 75 mg every other day and 
weekly doses up to 300 mg are being evaluated.
In addition to concurrent treatment with selumetinib, 
other MK-2206 combinations are being clinically evaluated. 
MET (also known as HGF) up-regulation has been shown to 
mediate resistance to EGFR inhibition, and preclinical studies 
reported at the meeting reveal that this resistance to EGFR 
inhibition is overcome with the addition of MK-2206. A phase 
II trial (NCT01294306) of MK-2206 with erlotinib in patients 
who benefited from and then progressed on erlotinib is cur-
rently accruing subjects. In relapsed small-cell lung cancer 
patients, a trial of topotecan versus topotecan with MK-2206 
is under development.
FUTURE DIRECTIONS
The RAS/RAF/MEK/Erk pathway underlies carcino-
genesis in multiple tumor types but has been a difficult target 
for drug therapy. Successful MEK-directed treatment of lung 
cancer potentially depends on two factors: identification of 
biomarkers to predict sensitivity and the selection of optimally 
beneficial drug combinations. At this time, RAS mutation may 
be the most reliable predictor of a cancer cell’s dependence 
on this pathway but other techniques have been evaluated to 
refine selection further. Concurrent treatment with cytotoxic 
agents has shown early promise in phase II trials. Dual target-
ing of MEK with inhibition of other kinases in the same path-
way (such as EGFR) or with inhibition of a parallel pathway 
(such as the PI3K/Akt pathway) are also promising directions 
for ongoing trials.
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